Cancer Biological Therapy Market by Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines), Route of Administration (Intramuscular, Intravenous, Subcutaneous), End-Users - Global Forecast 2024-2030

Cancer Biological Therapy Market by Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines), Route of Administration (Intramuscular, Intravenous, Subcutaneous), End-Users - Global Forecast 2024-2030


The Cancer Biological Therapy Market size was estimated at USD 64.95 billion in 2023 and expected to reach USD 72.42 billion in 2024, at a CAGR 11.60% to reach USD 140.04 billion by 2030.

Global Cancer Biological Therapy Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Biological Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Biological Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biological Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Biogen Inc., bluebird bio, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Incyte Corp, Johnson & Johnson Services, Inc,, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., Sanofi SA, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage



This research report categorizes the Cancer Biological Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Cancer Growth Blockers
Monoclonal Antibodies
Vaccines
Route of Administration
Intramuscular
Intravenous
Subcutaneous
End-Users
Hospitals
Specialty Centers
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cancer Biological Therapy Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Biological Therapy Market?
3. What are the technology trends and regulatory frameworks in the Cancer Biological Therapy Market?
4. What is the market share of the leading vendors in the Cancer Biological Therapy Market?
5. Which modes and strategic moves are suitable for entering the Cancer Biological Therapy Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cancer Biological Therapy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of cancer with increased healthcare expenditure
5.1.1.2. Increasing awareness regarding benefits of cancer biological therapy
5.1.1.3. Favorable government policies for cancer based therapies
5.1.2. Restraints
5.1.2.1. Capital intensive treatment
5.1.3. Opportunities
5.1.3.1. Ongoing technological advancements in cancer biologics
5.1.3.2. Rising research and development activities for development of efficient cancer biological therapies
5.1.4. Challenges
5.1.4.1. Probable effects of anti-cancer drug therapy
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cancer Biological Therapy Market, by Product
6.1. Introduction
6.2. Cancer Growth Blockers
6.3. Monoclonal Antibodies
6.4. Vaccines
7. Cancer Biological Therapy Market, by Route of Administration
7.1. Introduction
7.2. Intramuscular
7.3. Intravenous
7.4. Subcutaneous
8. Cancer Biological Therapy Market, by End-Users
8.1. Introduction
8.2. Hospitals
8.3. Specialty Centers
9. Americas Cancer Biological Therapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cancer Biological Therapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cancer Biological Therapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie, Inc
13.1.2. Amgen Inc.
13.1.3. Astellas Pharma Inc.
13.1.4. AstraZeneca PLC
13.1.5. Bausch Health Companies Inc.
13.1.6. Bayer AG
13.1.7. Biogen Inc.
13.1.8. bluebird bio, Inc.
13.1.9. Bristol-Myers Squibb Company
13.1.10. Eisai Co., Ltd.
13.1.11. Eli Lilly and Company
13.1.12. F. Hoffmann-La Roche Ltd
13.1.13. Gilead Sciences, Inc.
13.1.14. GlaxoSmithKline PLC
13.1.15. Hikma Pharmaceuticals PLC
13.1.16. Incyte Corp
13.1.17. Johnson & Johnson Services, Inc,
13.1.18. Merck & Co., Inc.
13.1.19. Novartis AG
13.1.20. Otsuka Pharmaceutical Co., Ltd
13.1.21. Pfizer Inc.
13.1.22. Sanofi SA
13.1.23. Spectrum Pharmaceuticals, Inc.
13.1.24. Takeda Pharmaceutical Company Limited
13.1.25. Teva Pharmaceutical Industries Ltd
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. CANCER BIOLOGICAL THERAPY MARKET RESEARCH PROCESS
FIGURE 2. CANCER BIOLOGICAL THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CANCER BIOLOGICAL THERAPY MARKET DYNAMICS
FIGURE 7. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 12. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings